Skip to main content
. 2022 Sep 1;6(4):451–464. doi: 10.7150/ntno.75045

Figure 2.

Figure 2

PLAD, PLD and F-Dox biodistribution in WEHI-164 tumor bearing mice at 72 h (PLAD, PLD) and 2 h (F-Dox) post-dose. Data are mean with SEM; n=7 for PLD and PLAD, n=5 for F-Dox. ANOVA with Tukey's test (A, B, D) or unpaired t-test (C); *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns: not significant. F-Dox: free doxorubicin, PLD: pegylated liposomal doxorubicin, PLAD: pegylated liposomal alendronate-doxorubicin.